News
-
-
COMMUNIQUÉ DE PRESSE
Moderna Receives Medicines and Healthcare Products Regulatory Agency Marketing Authorization in the UK for RSV Vaccine
Moderna's mRESVIA, an RSV vaccine, receives marketing authorization in the UK for adults 60+ to prevent lower respiratory tract disease by respiratory syncytial virus. Second approved product in the UK -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Moderna Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Updates
Moderna, Inc. reports Q4 revenues of $1.0B with a net loss of $(1.1)B. Forecasts 2025 revenue of $1.5-2.5B. Submitted 3 mRNA products for regulatory approval. Financial details and pipeline updates disclosed -
-
